BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31095676)

  • 1. Cost-effectiveness and Budgetary Impact of Hepatitis C Virus Testing, Treatment, and Linkage to Care in US Prisons.
    Assoumou SA; Tasillo A; Vellozzi C; Eftekhari Yazdi G; Wang J; Nolen S; Hagan L; Thompson W; Randall LM; Strick L; Salomon JA; Linas BP
    Clin Infect Dis; 2020 Mar; 70(7):1388-1396. PubMed ID: 31095676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
    Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
    Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
    Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study.
    Assoumou SA; Nolen S; Hagan L; Wang J; Eftekhari Yazdi G; Thompson WW; Mayer KH; Puro J; Zhu L; Salomon JA; Linas BP
    Am J Med; 2020 Nov; 133(11):e641-e658. PubMed ID: 32603791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.
    Dalgic OO; Samur S; Spaulding AC; Llerena S; Cobo C; Ayer T; Roberts MS; Crespo J; Chhatwal J
    Sci Rep; 2019 Nov; 9(1):16849. PubMed ID: 31727921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: A model-based cost-effectiveness analysis.
    Duchesne L; Dussault C; Godin A; Maheu-Giroux M; Kronfli N
    Int J Drug Policy; 2021 Oct; 96():103345. PubMed ID: 34176704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.
    Chugh Y; Premkumar M; Grover GS; Dhiman RK; Teerawattananon Y; Prinja S
    BMJ Open; 2021 Feb; 11(2):e042280. PubMed ID: 33589457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers.
    Epstein RL; Pramanick T; Baptiste D; Buzzee B; Reese PP; Linas BP; Sawinski D
    J Am Soc Nephrol; 2023 Feb; 34(2):205-219. PubMed ID: 36735375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programs.
    Schackman BR; Gutkind S; Morgan JR; Leff JA; Behrends CN; Delucchi KL; McKnight C; Perlman DC; Masson CL; Linas BP
    Drug Alcohol Depend; 2018 Apr; 185():411-420. PubMed ID: 29477574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
    Chaillon A; Rand EB; Reau N; Martin NK
    Clin Infect Dis; 2019 Nov; 69(11):1888-1895. PubMed ID: 30689769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
    Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
    Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
    McEwan P; Ward T; Yuan Y; Kim R; L'italien G
    Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs.
    Gutkind S; Schackman BR; Morgan JR; Leff JA; Agyemang L; Murphy SM; Akiyama MJ; Norton BL; Litwin AH; Linas BP
    Clin Infect Dis; 2020 Mar; 70(7):1397-1405. PubMed ID: 31095683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
    Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.
    Marco A; Domínguez-Hernández R; Casado MA
    Rev Esp Sanid Penit; 2020; 22(2):66-74. PubMed ID: 32697276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.